Report on External Proficiency Testing for the ABO and D Blood Group Typing Tests in Blood Centers (2015)

Lim, Young Ae; Cho, Hyun Soo; Choi, Young Sill; Jang, Choong Hoon; Lee, Mi Nam; Kwon, Jeong Ran; Kim, Jun Nyun; Kim, Hyun Ok

doi:10.17945/kjbt.2016.27.1.68

Cited by 6 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…D typing was duplicated using the manual tile method with the anti-D Bioclone (MAD2 clone; Ortho Clinical Diagnostics, Raritan, NJ, USA). Samples showing strong positive reactivity (grade 3+ to 4+) for both the automated and the manual tile tests were considered D+ and were not further tested [ 13 ]. Samples showing weak reactivity (agglutination strength of grade 2+ or weaker) with one or more D typing reagents used in an automated instrument and manual D typing were considered D-variants, and negative samples were subjected to weak D testing and/or RhCE phenotyping.…”

Section: Methodsmentioning

confidence: 99%

Weak D Testing is not Required for D? Patients With C?E? Phenotype

et al. 2018

View full text Add to dashboard Cite

BackgroundAlthough testing to detect weak D antigens using the antihuman globulin reagent is not required for D− patients in many countries, it is routinely performed in Korea. However, weak D testing can be omitted in D− patients with a C−E− phenotype as this indicates complete deletion of the RHD gene, except in rare cases. We designed a new algorithm for weak D testing, which consisted of RhCE phenotyping followed by weak D testing in C+ or E+ samples, and compared it with the current algorithm with respect to time and cost-effectiveness.MethodsIn this retrospective study, 74,889 test results from January to July 2017 in a tertiary hospital in Korea were analyzed. Agreement between the current and proposed algorithms was evaluated, and total number of tests, time required for testing, and test costs were compared. With both algorithms, RHD genotyping was conducted for samples that were C+ or E+ and negative for weak D testing.ResultsThe algorithms showed perfect agreement (agreement=100%; κ=1.00). By applying the proposed algorithm, 29.56% (115/389 tests/yr) of tests could be omitted, time required for testing could be reduced by 36% (8,672/24,084 min/yr), and the test cost could be reduced by 16.53% (536.11/3,241.08 USD/yr).ConclusionsOur algorithm omitting weak D testing in D− patients with C−E− phenotype may be a cost-effective testing strategy in Korea.

show abstract

Section: Methodsmentioning

confidence: 99%

Weak D Testing is not Required for D? Patients With C?E? Phenotype

et al. 2018

View full text Add to dashboard Cite

show abstract

“…These ABO blood group antigens are not a prerequisite for T cell sensitization for the production of antibodies and are poor inducers of T cell-specific response [ 7 - 10 ]. ABO antibodies are mostly IgM or IgG, which are formed by extrafollicular B-1 cells, whereas antipeptide antibodies are formed by follicular B-2 cells [ 11 - 13 ].…”

Section: Abo Blood Group Antigensmentioning

confidence: 99%

Transfusion support in hematopoietic stem cell transplantation

et al. 2023

View full text Add to dashboard Cite

Transfusion support for hematopoietic stem cell transplantation (HSCT) is an essential part of supportive care, and compatible blood should be transfused into recipients. As leukocyte antigen (HLA) matching is considered first and as the blood group does not impede HSCT, major, minor, bidirectional, and RhD incompatibilities occur that might hinder transfusion and cause adverse events. Leukocyte reduction in blood products is frequently used, and irradiation should be performed for blood products, except for plasma. To mitigate incompatibility and adverse events, local transfusion guidelines, hospital transfusion committees, and patient management should be considered.

show abstract

Annual Report on the External Quality Assessment Scheme for Transfusion Medicine in Korea (2017)

Lim

Cho

2018

J Lab Med Qual Assur

View full text Add to dashboard Cite

Here, we have reported results of the surveys on the external quality assessment scheme (EQA) of the Transfusion Medicine Program (TMP) in Korea that were carried out in 2017. The proficiency testing specimens were prepared at Ajou University Hospital, and sent to the participants biannually. The average accuracy rates (N=the number of participants) for ten different test items on the regular survey were as follows: ABO typing, 99.1%-99.9% (N=714); RhD typing, 99.3%-100.0% (N=695); crossmatching, 88.9%-98.5% (N=618); ABO subtyping, 80.7% and 96.0% (N=51); Rh CcEe antigen testing, 98.8%-100.0% (N=51); weak D test, 99.3% and 100.0 (N=150); antibody screening, 98.6%-100.0% (N=295); direct antiglobulin test (DAT) using a poly-specific reagent, 99.2%-100.0 (N=256); DAT using an immunoglobulin-G monospecific reagent, all 100.0% (N=68); DAT using a C3dmonospecific reagent, 83.6%-100.0% (N=72); antibody identification, 88.7%-99.2% (N=123); and ABO Ab titration, 84.6%-100.0% (N=73). The number of participants for the EQA for TMP in 2017 was much higher than that in 2016. Except for the case of ABO subtyping, excellent survey results for the 2017 EQA for TMP were obtained, compared to those in 2016. Thus, the EQA for TMP in 2017 should be helpful for improving the quality of the participating laboratories.

show abstract

Report on External Proficiency Testing for the ABO and D Blood Group Typing Tests in Blood Centers (2015)

Cited by 6 publications

References 1 publication

Weak D Testing is not Required for D? Patients With C?E? Phenotype

Weak D Testing is not Required for D? Patients With C?E? Phenotype

Transfusion support in hematopoietic stem cell transplantation

Annual Report on the External Quality Assessment Scheme for Transfusion Medicine in Korea (2017)

Contact Info

Product

Resources

About